NovaDigm Therapeutics

NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company’s founding scientists from the LA BioMed Institute at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” NovaDigm’s lead product candidates target Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA.